MA-HOLOGIC
21.9.2021 13:02:08 CEST | Business Wire | Press release
Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, today shared the findings from its inaugural Hologic Global Women’s Health Index , the world’s most comprehensive, globally comparative survey about women’s health.
Developed in partnership with leading analytics and advice firm Gallup, the Hologic Global Women’s Health Index is an unprecedented, in-depth examination of critical markers for women’s health, by country and territory, and over time. Its findings are based on the experiences of more than 60,000 women and girls from 116 countries and territories, captured in more than 140 languages. Conducted as part of the Gallup World Poll, which began in 2005, the Hologic Global Women’s Health Index represents the feelings and actions of approximately 2.5 billion women and girls.
Based on responses from the 120,000 total individuals surveyed, women’s health needs are not being met globally. The global score was 54 out of 100 on the Index, and no one country or territory scored more than 69. Country and territory rankings can be found here . Notably, 40% of those surveyed – equating to about a billion women and girls – said they had not talked to a healthcare professional in the last year, while approximately 60% – about 1.5 billion – were not tested for four common diseases that affect women’s health.
“Women’s health is the cornerstone of families, communities, societies and economies,” said Steve MacMillan, Hologic’s Chairman, President and Chief Executive Officer. “As a leader in the early detection, diagnosis and treatment of women’s health issues, we know firsthand that measurement is the key to improvement. We saw a clear need for more robust, quality data to track and measure women’s health on a global level — particularly as COVID-19 has worsened longstanding healthcare disparities. The Hologic Global Women’s Health Index is the first global survey that uniquely draws from women’s perspectives to determine priorities.”
The Hologic Global Women’s Health Index provides an actionable, science-backed data roadmap for improving life expectancy and quality of life for women and girls worldwide. To help countries and territories determine a strategy for ensuring a healthy future for women, the Index identifies five dimensions of women’s health that explain more than 80% of women’s average life expectancy at birth: Preventive Care, Opinions of Health and Safety, Emotional Health, Individual Health and Basic Needs. In the Index, countries and territories are ranked across each of these five dimensions, then those scores are combined to create an overall ranking. Positive improvements on any of the five dimensions could potentially help women live healthier, longer lives.
“In line with critical UN Sustainable Development Goals and the UN General Assembly theme of ‘Building Resilience Through Hope,’ we urge global healthcare and government leaders to use this data and the five dimensions to guide the development of actionable and measurable plans and investments that prioritize women’s health,” said MacMillan.
While the Hologic Global Women’s Health Index was initiated before COVID-19 affected the world, the pandemic and its effects on the already precarious state of women’s healthcare — including postponed or canceled preventive care examinations, increased poverty levels, and insufficient access to medical facilities and education — have created a more urgent need for world leaders and policymakers to prioritize women’s health.
“The COVID-19 pandemic has both exacerbated and shed light on longstanding gaps in access and quality of healthcare,” said Vipula Gandhi, Senior Managing Partner at Gallup. “The Index provides a baseline from which we can measure the state of women’s health globally. We hope this study will serve as a call to action for world leaders and policymakers as they navigate the global recovery.”
Hologic is committed to conducting the Global Women’s Health Index on a regular basis so world leaders can take action. This commitment builds on Hologic’s more than 30 years of championing women’s health around the world through its products for breast and cervical cancer screening, infectious disease detection, and gynecologic surgery, and its partnerships with numerous global initiatives promoting better access to healthcare .
Country and Territory Rankings Influenced by Disparities in Income and Health Systems
In this first year of the Hologic Global Women’s Health Index, no single country or territory scored more than 69 out of 100. Generally, most countries and territories that lead the world on the Index also lead the world in how much of their wealth they invest back into their health systems, including Austria, Switzerland and Norway. Overall, while women in high-income countries and territories were only 17% of the women surveyed in the Index, they collectively have at least a seven-point lead on the Index over all other women globally.
Conversely, the countries and territories with the lowest scores on the Hologic Global Women’s Health Index all share high income inequality and weak or destabilized infrastructure for healthcare. The countries and territories with the lowest scores on the Index are a mix of mostly low- and lower-middle income economies. Few countries and territories in this group score well in meeting women’s basic needs and are significantly lagging in the Preventive Care dimension.
Universal Challenges Around Preventive Care
“Preventive measures are a crucial first step to combating diseases and infections affecting life expectancy and fertility in women,” said Susan Harvey, MD, Vice-President of Global Medical Affairs, Hologic. “Failing to ensure women get routine testing for cancers, sexually transmitted diseases and infections, and cardiometabolic diseases can lead to larger complications that would otherwise be preventable if monitored or treated early.”
While international testing standards differ, the Hologic Global Women’s Health Index found that within the past 12 months, more than 1.5 billion women were not tested for any of four critical diseases for women: cancer, diabetes, high blood pressure and sexually transmitted diseases/infections (STDs/STIs).
- Just 12% of women worldwide reported being screened for any type of cancer.
- Globally, only about one in five (19%) women reported being screened for diabetes, the sixth leading cause of death for women around the world. In countries and territories with high obesity rates such as the United States, one in three women (34%) reported being tested.
- On average, only one in three women (33%) worldwide had their blood pressure tested despite heart disease being the leading cause of death globally for women and men.
- Fewer than one in nine women (11%) reported being tested for STDs/STIs, which are risk factors for further health issues like HIV, cancer and infertility.
A Holistic Approach to Women’s Health
Collectively, the world in 2020 felt the worst it has in 15 years. Global experiences of worry, stress, sadness and anger continued to rise and set new records. About four in ten women said they experienced worry (40%) and stress (38%) during a lot of the previous day.
Many women surveyed also expressed concerns about their safety and ability to meet basic needs like food and shelter.
- Two in three women (66%) — which translates into roughly 1.7 billion women — cited domestic violence as a widespread problem in their country.
- Nearly one in three (32%) — more than 800 million women — said they are afraid to walk alone at night.
- More than one in three (34%) — nearly 900 million women — said they struggled to afford food in the past year.
- Nearly three in ten (29%) — or nearly 700 million women — said they struggled to afford adequate housing for themselves and their families.
For more information about the Hologic Global Women’s Health Index and year one findings, please visit hologic.womenshealthindex.com .
About Hologic, Inc.
Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com .
Hologic and the Global Women’s Health Index are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries and territories.
About the Gallup World Poll
The Gallup World Poll is the most comprehensive and farthest-reaching survey of the world. The survey connects with more than 90% of the world's adult population through annual, nationally representative surveys with comparable metrics across countries and territories. Gallup, Inc. works with organizations across multilaterals, NGOs, private foundations, philanthropies and corporations to measure more than 100 crucial issues affecting people's lives via the World Poll. As a result, the World Poll has become an indispensable tool for global leaders and decision-makers who need to understand the hopes, dreams and behaviors of the people they serve.
Forward Looking Statements
This news release may contain forward-looking information that involves risks and uncertainties, including statements about the Company’s plans, objectives, expectations and intentions. There can be no assurance that these efforts will be successful, benefit the Company and its stockholders, or improve over time. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any changes in expectations or events, conditions or circumstances on which any such data or statements are based.
SOURCE : Hologic, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210921005231/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
